MedDataX Logo

Effect of a Lateral Nerve of the Thigh Block on Postoperative Pain After Total Hip Replacement Surgery

NCT ID: NCT02289937

Last Updated: 2014-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to evaluate the analgesic efficacy of the nervus cutaneous femoral lateralis (NCFL) blockade on postoperative pain after total hip replacement surgery. The NCFL-block is a pure sensory block. We hypothesized that the NCFL-block would reduced the postoperative pain without delaying mobilization.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative Anesthesia, Conduction Arthroplasty, Replacement, Hip

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ropivacaine

8 ml of ropivacaine 7,5 mg/ml will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided.

Group Type EXPERIMENTAL

Ropivacaine

Intervention Type DRUG

An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively

Intervention Type DEVICE

Placebo

8 ml of isotonic saline will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ropivacaine

Intervention Type DRUG

Placebo

Intervention Type DRUG

An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Naropin Saline, NaCl

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary total hip replacement

Exclusion Criteria

* general anaesthesia
* Allergy to local anesthetics of the amide type
* Revision surgery
* Bilateral surgery
* Chronic pain patient
* Women in the fertile age
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Daniel Hägi-Pedersen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Daniel Hägi-Pedersen

Consultant

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel Hägi-Pedersen, M.D., Ph.D.

Role: STUDY_CHAIR

Naestved Hospital, Department of Anaesthesiology

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-004501-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

001-2013

Identifier Type: -

Identifier Source: org_study_id